The State of Vitiligo 2025: A Fast-Moving Field With Slow-Moving Funding (Ep. 57)

In this closing 2025 episode, we unpack four decades of National Institute of Health (NIH) data, compare vitiligo’s budget to other autoimmune and skin diseases, and explain the “industry twist”: tiny public dollars helped build the science, while the commercial market is now booming. We also look at the big paradox: vitiligo research helped spark major ideas in modern medicine (think immune pathways that later shaped blockbuster therapies), yet the shared infrastructure vitiligo now needs — US-based biobanks, registries, and longitudinal cohorts — remains fragmented. Meanwhile, the commercial side is moving fast, with a billion-dollar market and crowded pipelines. Read the full report in two parts: The Vitiligo Paradox – Common Disease, Rare Funding Who Gets to Do Vitiligo Science?